Biodexa Announces Closing Of $6 0 Million Underwritten Public Offering, Including Full Exercise Of Overallotment Option businessinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from businessinsider.com Daily Mail and Mail on Sunday newspapers.
Adhera Therapeutics, Inc. (OTCMKTS:ATRX – Get Free Report) was the recipient of a significant increase in short interest during the month of November. As of November 30th, there was short interest totalling 11,800 shares, an increase of 81.5% from the November 15th total of 6,500 shares. Based on an average trading volume of 1,570,700 shares, […]
StockWatch: CAR-T Shares Mostly Flat as FDA Probes Risk of New Cancers genengnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from genengnews.com Daily Mail and Mail on Sunday newspapers.
Biodexa Pharmaceuticals (BDRX) to Acquire Exclusive Worldwide License to Tolimidone streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Biodexa Pharmaceuticals Plc's (BDRX) stock has risen by 157% on Monday following the announcement that it has secured the rights to tolimidone (formerly coded MLR-1023) from Adhera Therapeutics via an exclusive, worldwide, sub-licensable license from Melior Pharmaceuticals.